S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis

NCT03499808 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

NETWORK

Sponsor class

Conditions

Amorphous, Eosinophilic, and Acellular Deposit
Constipation
Diarrhea
Early Satiety
Gastrointestinal Hemorrhage
Hepatomegaly
Lymphadenopathy
Macroglossia
Nausea
Primary Systemic Amyloidosis
Purpura
Recurrent Primary Amyloidosis
Refractory Primary Amyloidosis

Interventions

BIOLOGICAL: Isatuximab
OTHER: Laboratory Biomarker Analysis

Sponsor

SWOG Cancer Research Network

Collaborators

[object Object]